Skip to Content

Etidronate Disease Interactions

There are 3 disease interactions with etidronate:


Etidronate (applies to etidronate) osteomalacia

Major Potential Hazard, High plausibility. Applicable conditions: Vitamin D Deficiency

The use of etidronate (for the treatment of Paget's disease or the treatment/prevention of heterotopic ossification) is contraindicated in patients with clinically overt osteomalacia. Etidronate can inhibit bone mineralization, which has resulted in osteomalacia and bone fractures in some patients. Accumulation of unmineralized osteoid is usually noticeable during prolonged, continuous use of high dosages (10 to 20 mg/kg/day) but may occur at lower dosages when use exceeds 6 months. The newer bisphosphonates (e.g., alendronate, pamidronate, risedronate, and tiludronate) do not cause mineralization defects and may be more appropriate for patients with osteomalacia, although clinical data may be lacking for the treatment of some conditions for which etidronate is used.


  1. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN.
  2. Evans RA, Dunstan CR, Hills E, Wong SY "Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone." Aust N Z J Med 13 (1983): 277-9
  3. Mautalen C, Gonzalez D, Blumenfeld EL, Santini Araujo E, Schajowicz F "Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP)." Clin Orthop Jun (1986): 150-5
  4. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.
  5. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT "Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease." Lancet 1 (1984): 821-4
View all 5 references

Etidronate (applies to etidronate) upper gastrointestinal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Esophageal Disease, Peptic Ulcer, Gastroesophageal Reflux Disease

Etidronate administered orally may cause local irritation of the upper gastrointestinal mucosa. Its use is contraindicated in patients with esophageal abnormalities that delay esophageal emptying such as achalasia or strictures. Etidronate should be used with caution in patients with active upper gastrointestinal problems, such as Barrett's esophagus, dysphagia, gastritis, duodenitis, ulcers, etc, as cases of erosions, bleeding and perforation have been reported. Patients should be instructed to discontinue treatment immediately and seek medical attention if they develop dysphagia, retrosternal pain, or new or worsening heartburn.


Etidronate (applies to etidronate) renal dysfunction

Moderate Potential Hazard, High plausibility.

Etidronate is eliminated intact by the kidney. There is no experience to specifically make recommendations in patients with impaired renal function. Etidronate dosage should be reduced when reductions in glomerular filtration rates are present. Patients with renal impairment should be closely monitored.


  1. "Product Information. Didronel I.V. Infusion (etidronate)." MGI Pharma Inc, Minnetonka, MN.
  2. "Product Information. Didronel Tablets (etidronate)." Procter and Gamble Pharmaceuticals, Cincinnati, OH.

Etidronate drug interactions

There are 162 drug interactions with etidronate

Etidronate alcohol/food interactions

There are 2 alcohol/food interactions with etidronate

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.